In a double-blinded RCT examining nasoduodenally delivered FMT for metabolic syndrome, Kootte et al39 did not find significant differences in their primary outcome measure (change in intestinal microbiota in relation to insulin sensitivity at 18 weeks), nor did they observe a significant change in BMI or SCFA levels at any study time point. This evidence concerns the gene INS and metabolic syndrome.